TC Biopharm (Holdings) Plc (TCBPY)
- Previous Close
0.3000 - Open
0.3000 - Bid 0.3000 x --
- Ask 0.4000 x 312500
- Day's Range
0.3000 - 0.3500 - 52 Week Range
0.0800 - 200.0000 - Volume
591 - Avg. Volume
353,031 - Market Cap (intraday)
205,196 - Beta (5Y Monthly) 0.34
- PE Ratio (TTM)
-- - EPS (TTM)
-4,933.5498 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
tcbiopharm.comRecent News: TCBPY
View MorePerformance Overview: TCBPY
Trailing total returns as of 5/8/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TCBPY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TCBPY
View MoreValuation Measures
Market Cap
205.20k
Enterprise Value
1.07M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.08
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-98.20%
Return on Equity (ttm)
-577.04%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-11.57M
Diluted EPS (ttm)
-4,933.5498
Balance Sheet and Cash Flow
Total Cash (mrq)
1M
Total Debt/Equity (mrq)
82.50%
Levered Free Cash Flow (ttm)
-6.03M